MétaCan
Menu
← Back to cohort

Safety and Efficacy of Low Molecular Weight Heparins for Hemodialysis in Patients with End-Stage Renal Disease: A Meta-Analysis of Randomized Trials.

2004· article· en· W2979925754 on OpenAlexaff
Wendy Lim, Mark Crowther

Bibliographic record

VenueBlood · 2004
Typearticle
Languageen
FieldMedicine
TopicVenous Thromboembolism Diagnosis and Management
Canadian institutionsMcMaster University
Fundersnot available
KeywordsMedicineHemodialysisEnd stage renal diseaseRandomized controlled trialDialysisPopulationThrombosisLow molecular weight heparinInternal medicineExtracorporealClinical trialAnticoagulantIntensive care medicineSurgery

Abstract

fetched live from OpenAlex

Abstract Background: The anticoagulant management of patients with thromboembolic disease who also have end-stage renal disease is a frequently encountered and unresolved clinical problem. Low molecular weight heparins (LWMHs) are the preferred initial treatment for these disorders but are renally excreted, and generally avoided in patients with renal failure due to concerns of bioaccumulation and increased bleeding risks. Unfractionated heparin (UFH) remains the primary anticoagulant used in this patient population despite the efficacy and convenience of LMWHs. Although LMWHs are typically not used to treat thrombosis in patients with end-stage renal disease, they are frequently used during hemodialysis to prevent thrombosis of the extracorporeal dialysis circuit. While there are no randomized data evaluating the safety and efficacy of LMWHs in these patients, randomized trials have been performed using LMWHs in the setting of hemodialysis. We performed a systematic review and meta-analysis of these randomized trials summarizing this data. Purpose: To evaluate the safety and efficacy of LMWHs compared to UFH for preventing thrombosis of the extracorporeal dialysis circuit. Data sources: We identified studies using MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and FirstSearch, reviewed reference lists and contacted pharmaceutical companies. Study selection: We included randomized, controlled trials that compared a LMWH with another anticoagulant during hemodialysis in patients with end-stage renal disease, and reported at least one of the following outcomes: bleeding, extracorporeal circuit thrombosis, or anti-Xa levels. Data extraction: Two reviewers independently extracted data on methodologic quality, study design, clinical outcomes, and anti-Xa levels. Data synthesis: We included 17 trials in this systematic review, 11 of which were included in the meta-analysis. We found that LMWH did not significantly affect the number of bleeding events (relative risk [RR] 0.96, 95% CI, 0.27 to 3.43), bleeding assessed by vascular access compression time (weighted mean difference −0.87, 95% CI, −2.75 to 1.02) or extracorporeal circuit thrombosis (RR 1.15, 95% CI, 0.70 to 1.91) as compared with UFH. Conclusions: LMWHs appear to be as safe as UFH in terms of bleeding complications, and as effective as UFH in preventing extracorporeal circuit thrombosis. However, inferences from these trials assessing anticoagulation for patients undergoing hemodialysis will continue to be weak until larger, more rigorous randomized trials are conducted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.018
metaresearch head score (Gemma)0.038
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.018
Threshold uncertainty score0.095

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0180.038
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0180.045
Bibliometrics0.0040.005
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.275
Teacher spread0.255 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicVenous Thromboembolism Diagnosis and Management→French-language works237,207→